Black Diamond Therapeutics, Inc.
General ticker "BDTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $158.4M (TTM average)
Black Diamond Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -16.1%.
Estimated limits based on current volatility of 2.8%: low 1.65$, high 1.74$
Factors to consider:
- Total employees count: 21 (-12.5%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Regulatory and compliance, Clinical trial failure, Inability to raise capital, No sales and marketing organization, Market competition
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.52$, 4.00$]
- 2026-12-31 to 2027-12-31 estimated range: [1.83$, 4.54$]
Financial Metrics affecting the BDTX estimates:
- Positive: with PPE of 6.7 at the end of fiscal year the price was low
- Positive: 15.80 < Operating profit margin, % of 17.89
- Positive: 15.29 < Operating cash flow per share per price, % of 20.46
- Positive: Return on assets ratio (scaled to [-100,100]) of 13.52 > 10.70
- Positive: 69.38 < Shareholder equity ratio, % of 78.46 <= 81.92
- Positive: -40.59 < Investing cash flow per share per price, % of -31.02
- Negative: Industry earnings per price (median), % of -15.99 <= 0
Short-term BDTX quotes
Long-term BDTX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $70.00MM |
| Operating Expenses | $86.46MM | $78.78MM | $57.48MM |
| Operating Income | $-86.46MM | $-78.78MM | $12.52MM |
| Non-Operating Income | $4.02MM | $9.11MM | $9.85MM |
| R&D Expense | $59.35MM | $51.31MM | $33.56MM |
| Income(Loss) | $-82.44MM | $-69.68MM | $22.37MM |
| Net Income(Loss)* | $-82.44MM | $-69.68MM | $22.37MM |
| Stockholders Equity | $116.74MM | $83.28MM | $112.21MM |
| Assets | $158.57MM | $122.64MM | $143.01MM |
| Operating Cash Flow | $-66.72MM | $-62.30MM | $29.61MM |
| Capital expenditure | $0.03MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $16.35MM | $16.97MM | $-44.91MM |
| Financing Cash Flow | $71.93MM | $25.55MM | $-0.15MM |
| Earnings Per Share** | $-1.88 | $-1.27 | $0.39 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.